Myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and rearrangement of PDGFRA, PDGFRB or FGFR1 are established types of hematologic neoplasms according to the most recent World Health Organization (WHO) classification. Such classification has therapeutic implications because these MLN-eos are driven by chimeric oncoproteins, including targetable receptor or non-receptor tyrosine kinases (TKs).
/l). A repeat BM biopsy revealed a cellularity of nearly 100%, and significantly decreased megakaryocytes and erythroid precursors, without dysplastic features. Mast cells were absent. There was diffuse increase in thick reticulin with extensive intersections and focal coarse collagen bundles. Overall, the picture was consistent with a diagnosis of eosinophiliaassociated myeloproliferative neoplasm with myelofibrosis MF-2, unclassified. Conventional cytogenetic analysis, performed according to the protocols used in our clinical cytogenetics laboratory as previously described, 6 confirmed the abnormal karyotype in 20/20 metaphases (Supplementary Figure 1A) . Fluorescence in-situ hybridization (FISH) analyses for BCR-ABL or rearrangements of PDGFRA or PDGFRB were negative. Real-time PCR failed to detect the JAK2V617F or MPLW515K gene mutations. A next-generation sequencing-based analysis for the detection of cancer-associated mutations in 53 genes was negative (Supplementary Table 1 ).
BM cells tested by flow cytometry using an extensive T-cell panel did not show aberrant T-cell clones. Given the patient's cytogenetic abnormality, we performed a dual-color break-apart FISH test for ETV6 rearrangements. FISH was performed using an LSI ETV6 probe (Abbott Molecular, Inc., Des Plaines, IL, USA), which hybridizes to band 12p13 of chromosome 12. A total of 200 interphases were analyzed according to the protocols used in our clinical cytogenetics laboratory, using a cutoff of 3.2% for the FISH probe. A split signal was observed in 82% of the 200 interphases analyzed (Supplementary Figure 1B) . To identify the fusion partner of ETV6 we performed a first round of 3 0 -Rapid Amplification of cDNA Ends (RACE)-PCR using the first-strand cDNA as a template, primers located at ETV6 exons 4 and 5, and a universal adapter (5 0 -AGCAGAGTGACG-3 0 , homologous to the adapter sequence used to prime the first-strand cDNA synthesis). The diluted product of the first RT-PCR was submitted to nested PCR with ETV6 exon-5 primer and a universal adapter reverse primer ( Supplementary  Figures 2A and B) . The PCR products were separated by electrophoresis on a 1.5% agarose gel and purified (sequences of all PCR primers used are listed in Supplementary Table 2 ). Since the 3 0 -RACE-PCR technology can give rise to artefacts, we performed RT-PCR using specific ETV6 forward and FLT3 reverse primers on the purified products of nested PCR. This resulted in an amplicon of 1050 base pairs, confirming that the two genes were indeed fusion partners. RT-PCR performed on a sample from a control patient negative for ETV6-FLT3 fusion failed to show a fusion product, confirming the specificity of the above RT-PCR primers for the ETV6-FLT3 fusion gene (Figure 1 ). These results indicated that the fusion occurred downstream of ETV6 exon-5 and upstream of FLT3 exon-15. Sequencing of the fusion product was not possible due to limited availability of the patient sample.
The patient was treated with the FLT3 inhibitor sorafenib at a dose of 400 mg twice daily. Owing to severe fatigue, the dose was reduced to 200 mg twice daily after 2 weeks. After 1.5 months of therapy, the patient's CBC showed a WBC of 3.8 Â 10 9 /l (normal differential), hemoglobin 9.8 g/dl and platelets 137 Â 10 9 /l. BM biopsy revealed marked hypocellularity, mild dysmyelopoiesis and mild dyserythropoiesis. Karyotype showed the t(12;13)(p13;q12) translocation in 2/15 metaphases. Collectively, these data indicated a complete hematological and very good partial cytogenetic response. Because of the patient's young age and availability of a fully matched sibling donor, she underwent consolidation with SCT. Conditioning consisted of fludarabine, busulfan and anti-thymocyte globulin. Only transient mild cutaneous and gastrointestinal graft-versus-host disease (GVHD) was observed post SCT. BM biopsies at 3 and 6 months post SCT showed complete morphological and cytogenetic remission. Eleven months after the diagnosis and 249 days post SCT, the patient is alive in clinical, marrow and cytogenetic complete remission, with no evidence of GVHD.
ETV6-FLT3-positive MLN-eos is an extremely rare condition, with only four cases reported to date. [3] [4] [5] Only two of the four patients received a FLT3 inhibitor (sunitinib and/or sorafenib), and the Accepted article preview online 23 May 2014; advance online publication, 17 June 2014 disease was rapidly fatal in three cases. The patient described by Vu et al. 3 presented with leukocytosis and eosinophilia, which progressed while on hydroxyurea and, subsequently, imatinib. It is unclear whether the progression occurred in the form of acute leukemia. The patient died despite the initiation of high-dose chemotherapy. The second patient reported 5 presented with T-cell lymphoblastic lymphoma (T-LBL) and concomitant myeloid neoplasm with eosinophilia, both of which were ETV6-FLT3-positive. The patient received intensive chemotherapy followed by SCT, and achieved a complete cytogenetic remission. A cytogenetic relapse post SCT responded to a tacrolimus taper, suggesting the existence of a graft-versus-leukemia effect. Walz et al. 4 reported two cases of ETV6-FLT3-positive MLN-eos. The first patient presented with increased BM myeloid blasts and nodal T-LBL, which initially responded to sunitinib but rapidly relapsed with increased BM blasts and complex karyotype. The patient was rechallenged with sorafenib but developed a resistant FLT3 mutation and died despite receiving high-dose chemotherapy. The second patient was diagnosed with MLN-eos after being treated for peripheral T-cell lymphoma, which subsequently relapsed as T-LBL with increased eosinophilia. His disease initially responded to sunitinib but rapidly progressed in the BM, with complex karyotype, and the patient died shortly afterwards.
Here, we report the first patient with chronic-phase ETV6-FLT3-positive MLN-eos to be treated upfront with sorafenib. The patient obtained a very good partial cytogenetic response after only 1.5 months of therapy. Given the aggressive clinical course described in the other published cases, the patient decided to proceed to SCT as soon as a response was documented.
FLT3 is the single most commonly mutated gene in hematologic malignancies, 7-9 but it is rarely a partner in fusion genes. ETV6-FLT3 has been associated with the development of MLN-eos. [3] [4] [5] In vitro studies have shown that the ETV6-FLT3 oncoprotein induced interleukin-3-independent growth of murine hematopoietic Ba/F3 cells. 3 The juxtamembrane domain of FLT3 appears critical for proliferation. 10 In addition, growth factor receptor-binding protein 2, an adaptor protein that mediates survival signaling in ligand-activated wildtype FLT3, may play a role in ETV6-FLT3 leukemogenesis.
11
Breakpoints involved in the formation of ETV6-FLT3 have been reported at exons 4 or 5 of ETV6 and exon 14 of FLT3. Whether the peculiar breakpoints found in our case (ETV6 exon 5-FLT3 exon 15) determined the more indolent behavior of the MLNeos remains to be ascertained, but clearly the ETV6-FLT3 fusion represented a 'driving lesion' in our patient. It is unknown whether long-term remissions are achievable after obtaining a cytogenetic response with FLT3 inhibitors and whether SCT is mandatory in patients with MLN-eos and ETV6-FLT3 as the sole abnormality.
In conclusion, ETV6-FLT3-positive MLN-eos appears to be a consistent clinical entity that could eventually fall under the WHOdefined category of MLN-eos. Given its extreme rarity, but important therapeutic implications due to the availability of FLT3 inhibitors, similar cases need to be reported to allow better understanding of their biology, natural history and treatment outcomes.
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LF conceived and designed the work that led to the submission, acquired and interpreted the data, and drafted and approved the final manuscript; MM GL, KPP, RL, UP and LML acquired data and revised and approved the final manuscript; treated the patient and revised and approved the final manuscript; SV conceived and designed the work that led to the submission, interpreted the data, revised and approved the final manuscript. Differentiation between essential thrombocythemia (ET) and polycythemia vera (PV) persists to be a matter of controversy, particularly in patients who present with increased hemoglobin (HB) levels accompanied by very high platelet counts. Although considered as a 'diagnostic gold standard', 1 the impact and practicability of red cell mass (RCM) measurements in patients with the clinical differential diagnosis of PV versus ET has to be discussed. 2, 3 In this context the diagnostic accuracy of different HB or hematocrit (HCT) threshold values and bone marrow (BM) morphology as surrogate markers for RCM have been considered. 4, 5 To capture PV patients with a borderline increase in HB (p18.5 g/dl in men and p16.5 g/dl in women), in addition to JAK2V617F or JAK2 exon 12 mutations and characteristic BM biopsy features, 6 a lowering of the HB and HCT values was postulated for the prospective revision of the 2008 WHO classification. 7 On the basis of the previous studies regarding so-called masked PV, threshold values included a HB level of 16.5 g/dl in men and 16 g/dl for women or a HCT level of 49% in men and 48% in women to be the optimal cutoff levels for distinguishing JAK2V617 ET from masked PV. 5 On the other hand, no knowledge exists on how many patients with World Health Organization (WHO)-confirmed ET including consistent BM features present with HB levels exceeding these postulated thresholds, that is, clinically suggesting (early/masked) PV. 3, 5 Our experience regarding this critical diagnostic pitfall was based on 891 patients with ET derived from an international study 8 (cohort 1) and diagnosed according to the classification proposed by the WHO. 9 Moreover, a validation sample (cohort 2) was considered including 248 patients selected from the Frankfurt database again with strictly WHO-defined ET diagnosis.
Examination of the HB values at diagnosis in our first cohort disclosed increased levels in about 5% without significant difference to the validation cohort (3%). Specifically, in 27 of 370 males (7.3%) in WHO-confirmed ET, a high level HB (X16.5 g/dl) was observed, and in the 521 female ET patients, 20 cases (3.8%) showed a HB exceeding 16.0 g/dl (Figure 1 ). Of note was that, in both cohorts these higher HB thresholds were associated with JAK2 positivity ranging between 70 and 80% (Table 1) . It is well known that patients with JAK2-mutated ET diagnosed according to the Polycythemia Vera Study Group (PVSG) criteria 1 may share a number of molecular genetic and clinical features with PV, and therefore it has been postulated that both may belong to a biological continuum representing different phenotypes of a single myeloproliferative neoplasm (MPN).
10,11
In a recently published study, JAK2V617F ET patients were reported to transform to PV with a cumulative risk of 29% at 15 years, whereas no transformation to PV was observed in CALRmutated ET patients.
11 According to the investigators, these findings were in keeping with the one-single disease hypothesis.
10
Regarding the design of this study, but especially recruitment of cases partly dating before 2002, it can be assumed that a considerable fraction of the total cohort of 745 ET patients would have been diagnosed according to the PVSG guidelines. 1 Moreover, 142 patients of this cohort 11 displayed evidence of erythrocytosis or leukocytosis about 22 months before the clinical diagnosis of PV, and in these patients the HB values, white blood cell counts, serum erythropoietin levels and degree of splenomegaly were above the usual range for ET according to the WHO definition. 8 Contrasting the significantly elevated rate of transformation into PV in this trial, 11 other authors found independent of mutation status in strictly WHO-defined large series of ET patients, a transformation rate to PV of only 0.9% after 10 years 12 or 5% after 12 years. 13 Concerning outcomes in our first cohort after a median follow-up of 6.2 years, clinical events were very few but their frequencies appeared to be similar to ET with lower HB values (major arterial thrombosis in 47 cases presenting with high HB level ET 9% vs 12% in the 844 cases with low HB level ET, death rate 11% vs 10%, respectively). Similar results could be assessed in the validation sample with only 2% of cases with overall PV transformation after 5 years of observation in the high HB level category of ET. A possible explanation for this disturbing discrepancy concerning incidences of PV transformation should include the inadvertent inclusion of so-called masked/early PV. 5, 13 It is well established that, although displaying characteristic BM features of PV, a number of these cases may clinically present as ET at onset before a later manifestation as overt PV.
14,15
In conclusion, a small fraction of ET patients (ranging between 3 and 5%) diagnosed according to the WHO criteria may present with higher HB values (X16.5 g/dl and X16.0 g/dl in males and females, respectively) and therefore clinically could mimic PV. However, about 20-30% of these cases do not have JAK2V617F or JAK2 exon 12 mutations and consequently cannot be regarded as PV. An accurate differentiation already at the beginning between ET with high HB and PV has certainly a significant impact on therapeutic modalities. On the other hand, all of these patients revealed characteristic BM features consistent with ET. This finding would indicate that BM morphology is a valid tool to distinguish these two MPN entities in mutation-positive or questionable cases and therefore may replace RCM measurements.
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